FDA has approved the combination of nivolumab and ipilimumab as the first‐line treatment of metastatic non‐small cell lung cancers that express PD‐L1 with no genomic tumor aberrations in EGFR or anaplastic lymphoma kinase (ALK).193. This evidence concerns the gene ALK and neoplasm.